IP Library Granted Patent US 8,026,056
Granted Patent B2
US 8,026,056 · App. 12/156,029 · Granted Sep 27, 2011

Compositions and methods for detecting

Assignee: Medical Diagnostic Laboratories, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,026,056
App. No.
12/156,029
Granted
Sep 27, 2011
Kind
B2
Abstract

Disclosed are oligonucleotides useful in methods for determining whether a sample contains Borrelia afzelii , a spirochete which is a causative agent of Lyme disease in humans. These oligonucleotides, which have nucleotide sequences derived from a coding segment of the gene encoding the p24 gene for the outer surface protein of Borrelia afzelii , are useful as forward and reverse primers for a polymerase chain reaction using nucleic acids from a biological sample as templates, and as probes for detecting any resultant amplicon. Detection of an amplicon indicates the sample contains Borrelia afzelii . Real-time PCR and detection using florescence resonance energy transfer is disclosed.

Claims (13)

1. A method of detecting the presence of Borrelia afzelii in a biological sample, comprising:

(a) mixing

(i) DNA extracted from said biological sample,

(ii) a primer pair comprising a forward primer and a reverse primer that target a p24 gene of Borrelia afzelii , and

(iii) a hybridization probe, in a PCR vessel, wherein said hybridization probe comprises a fluorescent moiety;

(b) amplifying said mixture of step (a), in a real-time PCR reaction, under conditions to allow production of an amplicon; and

(c) detecting a presence or absence of Borrelia afzelii , by detecting a presence or absence of a fluorescent signal resulting from the formation of said amplicon,

wherein the presence of a fluorescent signal is indicative of the presence of Borrelia afzelii,

wherein said forward primer consists of nucleotide sequence 379-401 set forth in SEQ ID NO: 1, said reverse primer consists of nucleotide sequence 103-126 set forth in SEQ ID NO: 2, and said hybridization probe consists of nucleotide sequence 134-163 of SEQ ID NO: 2.

2. A kit for PCR detection of Borrelia afzelii , comprising:

(a) a forward primer that consists of nucleotides 379-401 of SEQ ID NO: 1;

(b) a reverse primer that consists of nucleotides 103-126 of SEQ ID NO: 2; and

(c) a hybridization probe that consists of nucleotides 134-163 of SEQ ID NO: 2.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2018
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: MEDICAL DIAGNOSTIC LABORATORIES L. L. C.
Reel/Frame 046354/0817 →
SECURITY INTEREST Recorded Apr 27, 2018
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 046031/0381 →
SECURITY INTEREST Recorded Mar 1, 2016
From: MEDICAL DIAGNOTIC LABORATORIES, L.L.C.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 037963/0744 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 24, 2008
From: FEOLA, MELANIE; ADELSON, MARTIN; MORDECHAI, ELI; NOVAK, LISA
To: MEDICAL DIAGNOSTIC LABORATORIES, LLC
Reel/Frame 022053/0836 →
Continuity (2)
Provisional Application 60932642 · Jun 1, 2007
Related Publication 20090275023A1 · Nov 5, 2009